Evidence Is the New Currency of MedTech Market Access
Healthcare systems across the world are under pressure that shows no sign of easing. Ageing populations, rising chronic disease burdens, workforce shortages, and constrained budgets have created an environment in which every investment in technology must justify itself. Against this backdrop, MedTech innovation is not a luxury. It is a necessity. But necessity alone does not guarantee that every innovation deserves to succeed.
That distinction matters more than the industry often acknowledges. The history of MedTech is littered with technologies that generated significant commercial momentum before evidence of real-world benefit caught up, or failed to. Surgical robots adopted before comparative effectiveness data existed. Diagnostic tools deployed at scale before clinical utility was established. Digital health applications promoted on engagement metrics rather than health outcomes. In each case, the cost was not merely financial. It was the opportunity cost of resources directed away from interventions that genuinely worked.
The challenge for healthcare systems is not identifying innovation. It is identifying which innovations genuinely deserve adoption.
The Shift from Persuasion to Proof
Historically, commercial success in MedTech relied heavily on awareness, relationships, and sales execution. The assumption was simple: if enough people knew about a technology, adoption would follow. That assumption is now rapidly becoming outdated.
Healthcare decision-makers have become significantly more evidence focused. Commissioners, procurement teams, integrated care systems, HTA bodies, and clinical leaders are increasingly asking the same question: Show me the evidence. Not the theoretical model. Not the carefully selected case study. The evidence.
The balance of influence is moving away from persuasion and towards proof. Decision-makers are operating under intense financial pressure and growing expectations to demonstrate measurable value from every investment. As Ron Burgundy famously demonstrated, simply shouting louder does not make something true, credible, or worthy of attention. Technologies that can clearly demonstrate improvements in clinical outcomes, operational efficiency, or system sustainability are increasingly able to differentiate themselves. Those that cannot face a far steeper path, regardless of how compelling their narrative may appear.
This is where Real-World Data and Real-World Evidence have moved from supporting materials to strategic assets. Clinical efficacy may secure regulatory approval. Real-world effectiveness increasingly determines commercial success. Healthcare systems want to know whether outcomes achieved in trials can be replicated in everyday clinical practice, across different patient populations, care settings, and levels of clinical expertise. The question is no longer whether a technology works. The question is whether it works in the real world, for real patients, within real healthcare systems.
The strongest evidence programmes are those prepared to discover uncomfortable truths, identifying where value genuinely exists, where it does not, and where technologies may need refinement before wider adoption. That transparency ultimately strengthens both the credibility of the manufacturer and the confidence of healthcare systems.
Europe Raises the Bar
Nowhere has the demand for better evidence been more structurally codified than in Europe. Prior to 2025, a manufacturer seeking reimbursement across the five largest European markets was effectively running five separate HTA processes in parallel, each with its own comparators, endpoints, timelines, and tolerance for uncertainty. The same technology could be deemed highly beneficial in one country and insufficiently evidenced in another, not because the science differed, but because the questions being asked of it did.
Regulation (EU) 2021/2282, which entered into force in January 2025, is the most significant structural response to that fragmentation in the history of European healthcare policy. Its centrepiece is the Joint Clinical Assessment (JCA): a single, EU-level evaluation of the relative clinical effects of a new technology, conducted by the HTA Coordination Group. Once completed, Member States are legally required to use the JCA report as the clinical foundation for their national reimbursement decisions. They cannot repeat the clinical assessment. The clinical question is answered once, at EU level, for all 27 Member States simultaneously.
The phased rollout begins with oncology and Advanced Therapy Medicinal Products from January 2025, expands to orphan medicines in 2028, and reaches full implementation across all centrally authorised products by 2030. High-risk medical devices follow from mid-2026.
What This Means in Practice
The JCA process is structured around a PICO framework: Population, Intervention, Comparator, and Outcomes. The scoping of the PICO is the most consequential step in the entire process, because it defines the evidentiary question the JCA will answer. Critically, the PICO is not set by the manufacturer. It is determined by the assessment group, with input from Member States, patients, and clinical experts across the EU. Manufacturers can engage, but the final scope reflects the collective view of 27 countries with different clinical norms, comparator landscapes, and outcome preferences.
The practical implications are significant. Evidence packages must be designed to satisfy a consolidated, multi-country PICO from the outset, not the requirements of any single national body. The JCA also runs in parallel with the EMA regulatory review, eliminating the 12 to 18 month buffer that manufacturers previously used to refine their HTA dossiers after regulatory submission. Evidence strategy must now be integrated into clinical development planning from Phase 2 onwards, with endpoint selection, comparator choice, and data collection protocols all designed with the JCA in mind, years before the assessment takes place.
Equally important is what the JCA does not do. It does not replace national reimbursement decisions. Health economic modelling, budget impact analysis, and real-world evidence generation remain national responsibilities. The clinical layer is harmonised; the economic and contextual layers remain country-specific. A favourable JCA report is a necessary condition for European market access. It is not a sufficient one.
The Strategic Imperative
The EU HTA Regulation does not change the fundamental logic of market access. Technologies that demonstrate clear, credible, comparative clinical benefit will succeed. Those that cannot will struggle. What it changes is the architecture through which that demonstration must be made, raising the minimum evidence standard, compressing the timeline, and creating a single point of failure, or success, that affects all Member States simultaneously.
The organisations that will navigate this landscape most effectively are those that have already internalised a deeper truth: evidence is not a supporting activity but a strategic one. The time to build the evidence needed for European market access is not after regulatory approval. It is years before it.
Innovation remains essential. But in a world of finite resources and increasing scrutiny, evidence is becoming the language through which innovation earns the right to succeed. The test of innovation is not volume. It is value. And value, in the end, must be demonstrated, not asserted.
